drugset / Trial / NCT06915870

Comparison of Empagliflozin and Dapagliflozin in Patients With Heart Failure Taking Standard Treatment

NCT06915870

Completed 108 enrolled Fatima Maqsood
RandomizedParallel-groupSingle-blindTreatment

Summary

Participants were enrolled and randomly divided in two groups. In group A, participants were prescribed Dapagliflozin 10 mg daily. In group B, participants were prescribed Empagliflozin 10 mg daily. All participants were followed-up in OPD after 12 weeks for assessment of ejection fraction.

Timeline

Start
2024-07-12
Primary completion
2025-01-13
Completion
2025-01-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapagliflozin Small molecule 10 mg
Subject Empagliflozin Small molecule 10 mg